Oral Formulation of Insulin for Preterm Infants
- Conditions
- Premature Birth of Newborn
- Interventions
- Biological: Oral Formulation of InsulinBiological: Placebo
- Registration Number
- NCT01093638
- Lead Sponsor
- Elgan Pharma Ltd.
- Brief Summary
The study will evaluate the effect of oral formulation of insulin on preterm infants, born between 26-33 weeks of pregnancy, weighing over 750 grams, who meet the inclusion and exclusion criteria established in this protocol.
- Detailed Description
The study will aim to determine whether an oral formulation of insulin administration enhances gastrointestinal maturation. The gastrointestinal maturation will be evaluated by the ability of premature infants to achieve complete enteral feeds. The insulin concentration administered in the study is physiological and within the insulin concentration range present in human breast milk and colostrum.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 33
- Pre-term infants 26-33 weeks gestation.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Oral Formulation of Insulin Oral Formulation of Insulin Oral formulation of insulin fed concomitantly with premature infant formula Oral Formulation of Placebo Placebo Oral formulation of placebo fed concomitantly with premature infant formula
- Primary Outcome Measures
Name Time Method Number of days to achieve complete enteral feeding Up to 28 days or discharge and at 3 months of age
- Secondary Outcome Measures
Name Time Method Number of gastric residual > 2 ml/kg Up to 28 days or discharge, at 3 months of age Number of days to discharge Up to 28 days or discharge and at 3 months of age Number of gastric residual > 50% of previous feeding Up to 28 days or discharge and at 3 months of age Weight gain Up to 28 days or discharge and at 3 months of age
Trial Locations
- Locations (1)
NICU, Laniado Hospital
🇮🇱Netanya, Israel